Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 11588
Date Received: 16/06/2026
Summary:
Request in relation to medical records.
Date of Response: 24/06/2026
View Response: 11588.pdf
Freedom of Information Request Reference: 11574
Date Received: 10/06/2026
Summary:
I request the following information from the Chalmers GIC for the year 2025. 1. What percentage of patients assessed have been diagnosed with gender dysphoria and/or gender incongruence? 2. What % of patients assessed are prescribed cross sex hormones?
Date of Response: 29/06/2026
View Response: 11574.pdf
Freedom of Information Request Reference: 11562
Date Received: 05/06/2026
Summary:
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: •ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) •Amivantamab Monotherapy •Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) •Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel •Atezolizumab monotherapy (subcutaneous injection only) •Dabrafenib + Trametinib •Docetaxel monotherapy or in combination with Carboplatin/Cisplatin •Durvalumab •Gemcitabine •Nintedanib + Docetaxel •Nivolumab •Osimertinib •Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) •Paclitaxel •Pembrolizumab Monotherapy •Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) •Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) •Pemetrexed + Platinum (Carboplatin/Cisplatin) •RET Inhibitors (Pralsetinib, Selpercatinib) •Sotorasib •Tepotinib •Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin •Other active systemic anti-cancer therapy •Palliative care only •Amivantamab with carboplatin and pemetrexed •Cemiplimab with platinum-based chemotherapy •Adagrasib •Datopotamab deruxtecan •Amivantamab with lazertinib •Pembrolizumab subcutaneous injection Q2. Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 25/06/2026
View Response: 11562.pdf
Freedom of Information Request Reference: 11561
Date Received: 04/06/2026
Summary:
I would like to know how many patients who live in East Lothian attend these Pain Clinics in Leith.
Date of Response: 26/06/2026
View Response: 11561.pdf
Freedom of Information Request Reference: 11557
Date Received: 04/06/2026
Summary:
Please could you provide the following, as currently recorded: 1. A list of the GP clusters within NHS Lothian, and the Health and Social Care Partnership (HSCP) each cluster sits within. 2. For each cluster, confirmation of whether a Cluster Quality Lead (CQL) is currently appointed. 3. The name of the Cluster Quality Lead for each cluster, and the GP practice with which they are associated.
Date of Response: 29/06/2026
View Response: 11557.pdf
Freedom of Information Request Reference: 11556
Date Received: 03/06/2026
Summary:
Please provide the names of all independent sector providers, insourcing providers, private hospitals, clinics, Community Interest Companies (CICs) and other non-NHS organisations currently contracted by NHS Lothian to provide NHS-funded services in the following specialties: • Gynaecology • Dermatology • Orthopaedics • Urology • Diagnostic Imaging (including Ultrasound) • Diagnostic and Laboratory Services For each provider, please include: 1. Provider name 2. Service/specialty provided 3. Contract start date 4. Contract end date 5. Whether the provider is contracted directly by NHS Lothian or through a national framework/DPS arrangement.
Date of Response: 25/06/2026
View Response: 11556.pdf
Freedom of Information Request Reference: 11555
Date Received: 03/06/2026
Summary:
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: •Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Abemaciclib + Fulvestrant •Alpelisib + Fulvestrant •Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only •Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel •Atezolizumab •Capivasertib •Capecitabine as a single agent •Carboplatin + Paclitaxel •Elacestrant •Eribulin as a single agent or in combination •Everolimus + Exemestane •Fulvestrant as a single agent •Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Palbociclib + Fulvestrant •Parp Inhibitors (Olaparib/Talazoparib) •Pembrolizumab Monotherapy •Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide •Carboplatin + Paclitaxel + Pembrolizumab •Pertuzumab (Perjeta) + Trastuzumab (Herceptin) •Phesgo (Pertuzumab + Trastuzumab in a single injection) •Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Ribociclib + Fulvestrant •Sacituzumab Govitecan •Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent •Trastuzumab deruxtecan (Enhertu) •Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel •Trastuzumab emtansine (Kadcyla) •Any other active systemic anti-cancer therapy •Pembrolizumab subcutaneous injection Q2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease): Phesgo (Pertuzumab + Trastuzumab in a single injection) Pertuzumab (Perjeta) + Trastuzumab (Herceptin) Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel Trastuzumab deruxtecan (Enhertu) Trastuzumab emtansine (Kadcyla) Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) Abemaciclib + Fulvestrant Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) Ribociclib + Fulvestrant Capecitabine as a single agent Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Q3. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 25/06/2026
View Response: 11555.pdf
Freedom of Information Request Reference: 11553
Date Received: 03/06/2026
Summary:
I am requesting information under the Freedom of Information Act 2000 regarding Pfizer-BioNTech COVID-19 vaccine batch FN1664. Please provide any information held relating to batch FN1664 concerning: • temperature excursions; • cold-chain breaches; • storage deviations; • transportation incidents; • thawing, handling or expiry management issues; • safety assessments, incident summaries, investigation findings or corrective actions relating to the above.
Date of Response: 25/06/2026
View Response: 11553.pdf
Freedom of Information Request Reference: 11551
Date Received: 03/06/2026
Summary:
Please send me the most recent Matched Job Report for the Band 7 SPDN (Specialist Practitioner District Nurses) in NHS Lothian and the current Job Description, so I can see precisely how their job has now been re-evaluated at Agenda for Change Band 7 from Band 6. Please also let me know what back pay they are receiving.
Date of Response: 26/06/2026
View Response: 11551.pdf
Freedom of Information Request Reference: 11550
Date Received: 03/06/2026
Summary:
Please can you tell me what resources NHS Lothian provides for the treatment of Lipoedema? 1. How many Lipoedema clinics does NHS Lothian provide and what are the locations? 2. How many hours per week is treatment offered at each clinic? 3. How many NHS staff provide treatment and the working hours per week for each, or the overall hours allocated for treatment staff for the service, if this is easier to provide? 4. What total budget is allocated to the treatment of lipoedema by NHS Lothian? 5. How many patients are currently registered to use the lipoedema treatment service? 6. What is the recommended frequency for re-assessment or monitoring the progression of the condition in patients, seeing as lipoedema is not curable?
Date of Response: 25/06/2026
View Response: 11550.pdf
Freedom of Information Request Reference: 11548
Date Received: 02/06/2026
Summary:
In the last 6 months (December 25- May 26, please confirm if any Mental Health services have been outsourced: If yes, please confirm: -The service provided E.G ADHD, Autism etc (please provide breakdown for each service if applicable and include any alternative services such as yoga, pilates etc) -The name of the company each service was outsourced to -Is there a contract in place and the length of contract for each service provided (if applicable) -The value of each service in the last 6 months Please confirm how this contract was procured E.G Tender, Direct Award etc Please provide an email and contact name within the outsource provider
Date of Response: 25/06/2026
View Response: 11548.pdf
Freedom of Information Request Reference: 11544
Date Received: 01/06/2026
Summary:
Please could you confirm if NHS Lothian has any local guidelines for the treatment of these conditions. Has NHS Lothian published or updated any guidelines for the treatment of heart failure with reduced, preserved or mildly reduced ejection fraction since June 2023? If yes, please provide a copy.
Date of Response: 26/06/2026
View Response: 11544.pdf
Freedom of Information Request Reference: 11543
Date Received: 01/06/2026
Summary:
How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: •Adalimumab - Humira •Adalimumab Biosimilar •Etrasimod •Filgotinib •Golimumab - Simponi •Golimumab Biosimilar •Infliximab - Remicade •Infliximab Biosimilar •Mirikizumab •Ozanimod •Risankizumab •Tofacitinib •Upadacitinib •Ustekinumab - Stelara •Ustekinumab Biosimilar •Vedolizumab •Guselkumab
Date of Response: 25/06/2026
View Response: 11543.pdf
Freedom of Information Request Reference: 11542
Date Received: 01/06/2026
Summary:
Could you please send me the most recent “matched job report” for band 6 Team Lead within Theatres at Royal infirmary of Edinburgh. In addition could I also request the matched job report for a band 5 Operating department practitioner in theatres in Royal infirmary of Edinburgh. I have requested both of these so I can see how job evaluation points and levels were rewarded. For these requests could you please also tell me the date these reports were last evaluated?
Date of Response: 29/06/2026
View Response: 11542.pdf
Freedom of Information Request Reference: 11541
Date Received: 01/06/2026
Summary:
I write to request the current and past waiting times for ADHD and Autism assessments for children in Scotland. This should include the number of children on the list and period of time from referral until assessment. This refers to children up to and including 15 years of age. I would like this information for each year from 2019 to current date and broken down by each health board if possible. I would also like information on the number and identity of all health boards who accept the findings of privately funded assessments and offer appropriate treatment to children funded by the NHS.
Date of Response: 24/06/2026
View Response: 11541.pdf
Freedom of Information Request Reference: 11540
Date Received: 01/06/2026
Summary:
I wish to make a Freedom of Information Request for the number Significant Adverse Events Reviews taken place in 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024 & 2025. With a breakdown of each year & each medical area.
Date of Response: 29/06/2026
View Response: 11540.pdf
Freedom of Information Request Reference: 11539
Date Received: 01/06/2026
Summary:
I would like the following information relating to your endometriosis service: 1. The total number of patients on the endometriosis surgical waiting list as of 1st of June 2026 2. Of those, the number of patients awaiting joint surgery involving both a colorectal surgeon and a gynaecological/endometriosis surgeon. 3. The longest time any patient on that waiting list has been waiting, in weeks, as of 1st of June 2026. 4. Whether colorectal input to your endometriosis service is job-planned or arranged on an ad hoc basis.
Date of Response: 25/06/2026
View Response: 11539.pdf
Freedom of Information Request Reference: 11538
Date Received: 29/05/2026
Summary:
For the financial year 2024/25 (1 April 2024 to 31 March 2025), please provide the following information. If complete data for this period is not yet available, please provide the most recent 12-month period for which complete data is held, and specify the dates covered. 1. The total number of patients who presented to your emergency department(s) with paracetamol overdose or suspected paracetamol toxicity. 2. Of those presentations, how many involved patients aged 17 years or under. If possible, please break this down by the following age groups: 0-11 years, 12-15 years, 16-17 years. 3. Of all presentations, where this information is recorded, how many were classified as: (a) accidental overdose or therapeutic excess - defined as an unintentional overdose taken for therapeutic purposes; (b) intentional self-poisoning; (c) unknown or unclassified. 4. Of all presentations, how many involved a combination product containing paracetamol - such as a cold and flu remedy, co-codamol or similar - rather than paracetamol alone?
Date of Response: 25/06/2026
View Response: 11538.pdf
Freedom of Information Request Reference: 11537
Date Received: 29/05/2026
Summary:
1. The number of patients admitted to each of the health board's minor injuries and illness units, by unit, over the last four calendar years (2023, 2024, 2025 and 2026 to date). 2. May I have the total number of winter falls patients admitted to each MIIU in 2023, 2024, 2025 and 2026 to date.
Date of Response: 25/06/2026
View Response: 11537.pdf
Freedom of Information Request Reference: 11536
Date Received: 28/05/2026
Summary:
How many referrals from January 2025 to December 2025 were accepted in the Community mental health teams. How many referrals from January 2025 to December 2025 were rejected in the Community mental health teams. How many referrals from January 2025 to December 2025 were accepted in psychology services. How many referrals from January 2025 to December 2025 were rejected in psychology services. How many referrals from January 2025 to December 2025 were accepted in Psychiatry. How many referrals from January 2025 to December 2025 were rejected in Psychiatry. How many referrals from January 2025 to December 2025 were accepted in addiction services. How many referrals from January 2025 to December 2025 were rejected in addiction services. Between January 2025 to December 2025, what was the longest wait for people in addiction services to be assessed.
Date of Response: 25/06/2026
View Response: 11536.pdf
Freedom of Information Request Reference: 11534
Date Received: 27/05/2026
Summary:
As of the most recent date for which data is available, please provide: 1. The total number of individuals under the age of 18 currently on a waiting list for an: (a) autism assessment. (b) ADHD assessment. 2. The total number of adults currently on a waiting list for an: (a) autism assessment. (b) ADHD assessment
Date of Response: 19/06/2026
View Response: 11534.pdf
Freedom of Information Request Reference: 11533
Date Received: 25/05/2026
Summary:
Please could you provide me with the following for the period January-December 2025 for HMP Edinburgh and HMP Addiewell. If for whatever reason you do not have the data available for those dates, please instead provide that data for the previous calendar year (1 April 2024-end of March 2025). - Please confirm how many Temporary Doctors jobs were filled by agencies, stated in hours. - Please confirm your total agency spend for Temporary Doctors. - Please confirm how many Doctors jobs were filled by salaried / ongoing employees within the prisons, stated in hours. - Please confirm your total spend for salaried / permanent Doctors jobs (both full and part-time) within the prisons. - Please confirm your total overall spend on Doctors within prisons, including both salaried employees and temporary roles.
Date of Response: 29/06/2026
View Response: 11533.pdf
Freedom of Information Request Reference: 11532
Date Received: 25/05/2026
Summary:
I would like to request the following information relating to referrals for ADHD and Autism Spectrum Disorder (ASD) assessments within your Health Board area. Please provide the data separately for: 1. Children and young people services 2. Adult services Please also provide the data separately for: • ADHD assessments • ASD assessments For each calendar year: • 2024 • 2025 (to date, if full-year data are not yet available) Please provide the following information: Referral pathway data 1. The total number of referrals received from General Practitioners (GPs) requesting assessment for ADHD and ASD. 2. Of these referrals, the number that: a. Were rejected without further screening/triage b. Were accepted for screening/triage c. Progressed to a full diagnostic assessment Waiting time data 3. The average waiting time from referral receipt to initial response regarding the referral outcome (for example, acknowledgement, rejection, or acceptance). 4. The average waiting time from referral receipt to screening/triage appointment. 5. The average waiting time from referral receipt to full diagnostic assessment. If available, please provide waiting times in: • Mean average days/weeks and/or • Median waiting time
Date of Response: 19/06/2026
View Response: 11532.pdf
Freedom of Information Request Reference: 11531
Date Received: 25/05/2026
Summary:
Please provide the following information from the financial years 2020/2021 to the end of the financial year 2025/2026: 1)The total number of patients aged under 21 who presented, or were referred within your organisation with a diagnosis or suspected diagnosis of an asbestos-related disease, including but not limited to: mesothelioma, asbestosis, pleural plaques, pleural effusion attributed to asbestos exposure, or diffuse pleural thickening. 2)Please break this figure down by financial year. Where the number of cases in any given year is five or fewer, please state "<5" rather than the exact figure. 3)Please confirm whether your organisation holds any coded data for these conditions in patients aged under 21, even if no cases have been recorded during the period.
Date of Response: 19/06/2026
View Response: 11531.pdf
Freedom of Information Request Reference: 11529
Date Received: 19/05/2026
Summary:
1. Any data or analysis showing the impact of asylum seeker and refugee demand on NHS waiting times (GP appointments, mental health, hospital care). 2. Number of asylum seekers and refugees registered with GPs in Scotland.
Date of Response: 18/06/2026
View Response: 11529.pdf
Freedom of Information Request Reference: 11528
Date Received: 19/05/2026
Summary:
1. Total spend by NHS Scotland on mental health services for asylum seekers and refugees in the last three years. 2. Number of referrals for trauma, PTSD, or torture-related mental health issues. 3. Any specific funded programmes for refugee mental health.
Date of Response: 18/06/2026
View Response: 11528.pdf
Freedom of Information Request Reference: 11527
Date Received: 19/05/2026
Summary:
1. Total spend on mental health services for asylum seekers and refugees in the last three years. 2. Number of referrals to mental health services from this group. 3. Any specific trauma or torture survivor support programmes and their costs.
Date of Response: 18/06/2026
View Response: 11527.pdf
Freedom of Information Request Reference: 11523
Date Received: 22/05/2026
Summary:
Please provide the following information: • Trade Union Time (Facility Time): The total number of hours allocated for trade union duties and activities, broken down by recognised trade unions within the organisation. • Staff Headcount: The total number of employees who were relevant union officials during this period, including a distinction between full-time and part-time staff. • Pay Banding: A breakdown of the pay bandings (or salary scales) of the staff members who have been granted facility time. • Financial Cost: The total cost incurred by the organisation for trade union facility time, alongside the percentage of the total pay bill spent on it. • Time Allocation Percentage: The number of representatives who spent 0%, 1–50%, 51–99%, or 100% of their working hours on facility time.
Date of Response: 23/06/2026
View Response: 11523.pdf
Freedom of Information Request Reference: 11522
Date Received: 22/05/2026
Summary:
Please provide figures regarding staff sickness absence within your organization for the most recent complete financial year (e.g., 2024/2025) or calendar year. Specifically, I require a breakdown cross-referencing the following three criteria: 1. The Staff Pay Band / Grade (e.g., Agenda for Change Bands). 2. The Department / Business Unit / Directorate (e.g., Human Resources, Finance, Operations, Clinical Specialties). 3. The Recorded Reason for Absence (e.g., mental health/stress, musculoskeletal, respiratory). For each intersection of the criteria above, please provide: • The total number of staff members who had a recorded sickness absence. • The total number of working days lost.
Date of Response: 22/06/2026
View Response: 11522.pdf
Freedom of Information Request Reference: 11521
Date Received: 22/05/2026
Summary:
1: Current in-centre haemodialysis patient numbers Please provide the total number of patients receiving in-centre haemodialysis in the most recent complete available month for each dialysis unit in your area by name. Please also provide for each dialysis unit in your area by name the number of these patients prescribed: a) Two haemodialysis sessions per week b) Three haemodialysis sessions per week c) Any other frequency of haemodialysis (please specify frequency categories used) 2: Two haemodialysis sessions per week For the total number of patients prescribed two in-centre haemodialysis sessions per week (the total at point 1a above) please provide the total number who: a: Didn't originally start dialysis on two sessions per week and have since transitioned to 2 sessions per week. b: Started on two sessions per week due to renal unit capacity issues. c: Started on two sessions per week due to other reasons 3: Historical monthly patient numbers Please provide the data requested in Question 1 for each of the last twelve complete calendar months.
Date of Response: 22/06/2026
View Response: 11521.pdf
Freedom of Information Request Reference: 11519
Date Received: 20/05/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?  1.1 Avelumab (Bavencio) 1.2 Atezolizumab (Tecentriq) 1.3 Pembrolizumab (Keytruda) 1.4 Nivolumab (Opdivo) 1.5 Durvalumab (Imfinzi) 1.6 Erdafitinib (Balversa) 1.7 Enfortumab vedotin (Padcev) 1.8 Cisplatin 1.9 Carboplatin 1.10 Gemicitabine Q2. How many patients were treated with avelumab (Bavencio) for the following types of cancer in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? Merkel Cell Carcinoma (ICD-10 codes = C4A* and/or morphology code = 8247/3) Urothelial Carcinoma (ICD-10 codes = C65*, C66*, C67* and/or morphology code = 8120*, 8130*, 8131/3, 8122/3, 8031/3) Renal Cell Carcinoma (C64*) Other types of tumour Q3. How many patients with Renal Cell Carcinoma (RCC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 3.1 Avelumab + Axitinib Q4. How many patients with Urothelial Carcinoma (UC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 4.1 Avelumab Monotherapy Maintenance 4.2 Atezolizumab 4.3 Pembrolizumab Monotherapy 4.4 Pembrolizumab + Enfortumab vedotin 4.5 Nivolumab Monotherapy 4.6 Nivolumab + Cisplatin + Gemcitabine 4.7 Durvalumab Monotherapy Maintenance 4.8 Durvalumab + Gemcitabine + Cisplatin 4.9 Carboplatin+ Gemcitabine 4.10 Paclitaxel Monotherapy 4.11 Carboplatin + Paclitaxel 4.12 Cisplatin + Gemcitabine Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 5.1 Aflibercept – (Zaltrap only) 5.2 Bevacizumab 5.3 Cetuximab 5.4 Encorafenib 5.5 Fruquintinib 5.6 Nivolumab 5.7 Panitumumab 5.8 Pembrolizumab 5.9 Regorafenib 5.10 Trifluridine + Tipiracil (Lonsurf) Q6. How many patients were treated for Colorectal Cancer (ICD-10 codes C18*, C19*, C20*, D010, D011, D012) with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 6.1 Bevacizumab 6.2 Cetuximab 6.3 Encorafenib 6.4 Nivolumab 6.5 Pembrolizumab 6.6 Regorafenib 6.7 Trifluridine + Tipiracil (Lonsurf) Q7. How many patients were treated for Colorectal Cancer (ICD-10 codes C18*, C19*, C20*, D010, D011, D012) with the following combinations or chemotherapy and other agents in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 7.1 Bevacizumab + Trifluridine + Tipiracil 7.2 Bevacizumab + FOLFOX 7.3 Bevacizumab + FOLFIRI 7.4 Cetuximab + FOLFIRI 7.5 Cetuximab + FOLFOX 7.6 Cetuximab + FOLFIRINOX / FOLFOXIRI 7.7 Cetuximab Monotherapy 7.8 Panitumumab + FOLFIRI 7.9 Panitumumab + FOLFOX 7.10 Panitumumab + FOLFIRINOX / FOLFOXIRI 7.11 Capecitabine + Oxaliplatin (XELOX) 7.12 Capecitabine + Irinotecan (XELIRI)
Date of Response: 18/06/2026
View Response: 11519.pdf
Freedom of Information Request Reference: 11518
Date Received: 20/05/2026
Summary:
I would appreciate it if you could provide the following information for the period from 1 January 2020 to the present: 1. The total number of cyber security incidents affecting your organisation, broken down by year. 2. The number (or best estimate) of incidents involving network-connected medical devices within your organisation. 3. A high-level breakdown of incident types (e.g. ransomware, malware, unauthorised access, denial of service). 4. A high-level summary of operational impact (e.g. service disruption, delayed care, system downtime, device isolation). 5. Any high-level trends observed over time. 6. Any aggregated information on common causes or contributing factors.
Date of Response: 18/06/2026
View Response: 11518.pdf
Freedom of Information Request Reference: 11517
Date Received: 20/05/2026
Summary:
I request the following information from the Chalmers GIC please. 1. Do all patients have a psychological assessment before they (a) start cross sex hormones (b) are referred for surgery? 2. If yes how many appointments do they have and how long is each appointment. 3. How many clinicians are involved in these assessments and please state the speciality of these clinicians? 4. Please share the protocol for the psychological assessments. 5. Please share the protocol you follow when assessing a patient for surgery referral. 6. Is there a consent process within GICs prior to referring a patient for surgery? 7. If yes please share a copy of the protocol and the consent form(s). 8. When referring patients for hysterectomy is one of the reasons to mitigate the risk of endometrial cancer (testosterone increases the risk of uterine cancer in women)?
Date of Response: 23/06/2026
View Response: 11517.pdf
Freedom of Information Request Reference: 11515
Date Received: 19/05/2026
Summary:
I am not satisfied that the substance of my request, which specifically asks for evidence of partnership agreement, was met. Speaking to my local Unite representative, they have no knowledge of changes to parking permit eligibility being discussed and agreed with them. I'd be grateful if you could provide the minutes to all the meetings when it was discussed and agreed that non-NHS Lothian staff would be refused permits for the RIE site. As a non-NHS Lothian staff member I have applied for a parking permit every year since 1999, so I question the statement that allocation rules were relaxed only because of Covid. Please can you tell me how policy changes that affect me are communicated?
Date of Response: 25/06/2026
View Response: 11515.pdf
Freedom of Information Request Reference: 11514
Date Received: 20/05/2026
Summary:
Please provide responses to the following questions: 1. What established and currently used detransition pathway does your service provide for detransitioners and desisters? 2. If no formal detransition pathway currently exists, is any detransition pathway presently being developed or established? 3. If a detransition pathway is currently established and being used, please provide: o A copy of the pathway; o Any related policies, procedures, guidance documents, or protocols used to support detransitioners and desisters; o Any clinical standards or safeguarding procedures associated with this care. 4. If a detransition pathway is currently being established, please provide further information regarding: o Who is involved in developing the pathway; o Whether any third-party organisations, charities, advocacy groups, or external stakeholders are providing input; o Whether lived experience input from detransitioners or desisters is being considered or utilised in the development process. 5. Please provide the number of detransitioners and desisters: o Currently using your services; o Who have previously used your services; o Referred to your services within the last five years. 6. Please provide information on how detransitioners and desisters are recorded or registered within your service, including but not limited to: o Any DSM diagnostic classifications used; o Any ICD-10 or ICD-11 diagnostic or administrative coding used; o Any internal terminology, categories, or recording systems used to identify detransitioners or desisters within patient records. 7. Please also provide any available data, reports, audits, reviews, or internal assessments relating to detransitioners and desisters within your service.
Date of Response: 23/06/2026
View Response: 11514.pdf
Freedom of Information Request Reference: 11513
Date Received: 19/05/2026
Summary:
I would be grateful if you could provide the following information regarding the software systems used within your organisation for documenting and reporting in women’s health services. For each of the clinical areas listed below, please provide: 1. The name of the reporting/documentation system currently in use 2. The supplier/vendor of the system 3. The contract start date 4. The contract duration (or term length) 5. The contract expiry/renewal date Clinical Areas Please respond to each area individually: 1. Obstetrics What reporting or documentation system is currently used? 2. Fetal Echocardiography (Fetal Echo) What reporting or documentation system is currently used? 3. Fetal Neurosonography (Fetal Neurosono) What reporting or documentation system is currently used? 4. Delivery / Labour Ward Documentation What system is used to support delivery records and labour documentation? 5. CTG Monitoring What system is used for cardiotocography (CTG) monitoring and reporting? 6. Partogram What system is used to record and manage partograms (including whether digital or paper-based)? 7. Gynaecology What reporting or documentation system is currently used? 8. Colposcopy What reporting or documentation system is currently used? 9. Breast Clinics What reporting or documentation system is currently used? Additional Clarifications • Where multiple systems are used within a single area (e.g. separate systems for imaging and reporting), please include details for each. • If any of the above services are not provided in-house, please confirm this. • If systems are part of a wider EPR/EHR platform, please specify the module name where possible.
Date of Response: 18/06/2026
View Response: 11513.pdf
Freedom of Information Request Reference: 11512
Date Received: 19/05/2026
Summary:
I would like to request access to existing recorded information held by NHS Lothian relating to life support ventilators (ICU, HDU, Non Invasive Ventilation, and JET ventilators). Please provide an extract from the Board’s current equipment or asset register showing all ventilators in use across the Board’s sites, including: • Royal Infirmary of Edinburgh • Western General Hospital • St John’s Hospital, Livingston • Royal Hospital for Children and Young People • Royal Edinburgh Hospital • All associated community hospitals and community health services across Lothian For each ventilator, please include: 1. Ventilator Details • Manufacturer • Model • Year of purchase (If the purchase year is not recorded, please provide the installation year instead.) 2. Replacement / Upgrade Plans • If held, confirmation of whether ventilator replacement or upgrade is recorded as planned within the next 24 months (Yes/No only – no further detail required.) 3. Format If the information is already held within a single document or register, please provide that document.
Date of Response: 26/06/2026
View Response: 11512.pdf
Freedom of Information Request Reference: 11511
Date Received: 19/05/2026
Summary:
Under the Freedom of Information Act, I would like to request information regarding the Brand and date of Commissioning for Neurophysiology Equipment for EEGs and NCS/EMG diagnostic investigations at the following Hospitals within the Trust. Western General Hospital, Edinburgh Royal Hospital for Sick Children, Edinburgh Royal Infirmary of Edinburgh
Date of Response: 18/06/2026
View Response: 11511.pdf
Freedom of Information Request Reference: 11510
Date Received: 18/05/2026
Summary:
1. The names, contact numbers/email of all members and positions of all OT team members (occupational therapist) that works in the Western general hospital and the royal infirmary (Edinburgh). Since the year 2026 2. Pease provide what percentage of patients been have been signed off as appropriate by an OT (occupational therapist) for discharge from hospital but the patient has subsequently returned to hospital in the next 14 days. 3. Please also break down the above request by the OT individual who 'signed' off the hospital discharge.
Date of Response: 12/06/2026
View Response: 11510.pdf
Freedom of Information Request Reference: 11509
Date Received: 19/05/2026
Summary:
1. Please provide your total annual spend (for each of the last three financial years, FY23/24, FY24/25, FY25/FY26) on ADHD and Autism assessments, broken down by: a. Total annual spend by third party private provider* b. For each third party private provider, total annual spend by assessment type (ADHD / Autism) 2. Please provide your total number of patients (for each of the last three financial years, FY23/24, FY24/25, FY25/FY26) on ADHD and Autism assessments, broken down by: a. Total number of patients assessed by third party private provider* b. For each third party private provider, total number of patients assessed by assessment type (ADHD / Autism) 3. For each third party private provider, please indicate the contract type (block / activity-based), start date and end date Please include volumes from NHS Trusts within your ICB that may deliver these services, and also third party private providers (or indicate if this is not possible) FY is defined as a year starting in April and ending in March. For example, FY23/24 starts on 1 April 2023 and ends on 31 March 2024.
Date of Response: 26/06/2026
View Response: 11509.pdf
Freedom of Information Request Reference: 11508
Date Received: 19/05/2026
Summary:
1. Does your maternity service routinely collect and record data relating to social risk, however this may be termed locally (e.g. vulnerability, complex social factors, social needs)? (yes/no) 2. If yes to Q1: approximately how many women using your maternity services were identified as having at least one social risk factor in the financial year 2024/25, where such data are routinely recorded? If an exact figure is not readily available, an estimate or the most recent available figure would be helpful. 3. Does your maternity service currently use the MatDAT (Maternity Disadvantage Assessment Tool), or any other standardised tool, to assess social risk in pregnancy/postnatally? (yes/no; if yes, please specify) 4. At which points during maternity care are social risk assessments routinely completed or reviewed? (e.g. booking appointment, 28 weeks, admission for birth, postnatal care) 5. Which Electronic Patient Record (EPR) system is primarily used in your maternity service to document social risk? (e.g. Badgernet, K2, EPIC)
Date of Response: 18/06/2026
View Response: 11508.pdf
Freedom of Information Request Reference: 11506
Date Received: 19/05/2026
Summary:
I would like to request copies of any decarbonisation, Net Zero, Heat decarbonisation or energy transition plans produced by the Health Board by Jacobs and/or Energy Systems Catapult from 2019 to present. This Includes any: • Net Zero Roadmaps • Heat Decarbonisation plans • Energy masterplans • Heat Network studies • Carbon reduction strategies. • Supporting presentations or reports. Where possible, I would like to request: • Final versions of Documents. • Executive Summaries. • Appendices and Technical Modelling Outputs where publicly releasable. • Any associated programme timelines or implementation plans.
Date of Response: 12/06/2026
View Response: 11506.pdf
Freedom of Information Request Reference: 11505
Date Received: 19/05/2026
Summary:
I wish to make a Freedom of Information Request for the amount spent on locum Vascular Sturgeons in 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024 & 2025. With a breakdown of each year.
Date of Response: 08/06/2026
View Response: 11505.pdf
Freedom of Information Request Reference: 11504
Date Received: 18/05/2026
Summary:
Question 1. How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust? Question 2. How many patients have been treated in the last 4 months (January to April 2026) with the following products: • Evrysdi (Risdiplam) If available, please provide the split of the number of patients treated with Evrysdi (Risdiplam) by TABLET and SOLUTION formulations. • Spinraza (Nusinersen) • Zolgensma (Onasemnogene)
Date of Response: 12/06/2026
View Response: 11504.pdf
Freedom of Information Request Reference: 11502
Date Received: 18/05/2026
Summary:
I wish to formally request a Freedom of Information Request, noting each and every contact which has been made to me, dates of same, method of informing me and the alleged appointments I have missed. Who is this faceless Waiting List Officer, and what does their role involve and what authority do they have.
Date of Response: 11/06/2026
View Response: 11502.pdf
Freedom of Information Request Reference: 11500
Date Received: 18/05/2026
Summary:
This request forms part of a service benchmarking exercise to better understand variation in clinical service models, workforce allocation and diagnostic activity across NHS providers. There are no plans at this stage for the use of this information other than for my personal interest. To support this request, I have attached a structured questionnaire designed to capture the relevant information in a clear and consistent format. The questionnaire asks for information relating to: • The number of sites providing ophthalmology and Visual Fields services • Staffing arrangements, including skill mix and sessional allocation • Activity levels, including the number of tests undertaken per session or day • Equipment used and standard testing protocols followed • Appointment types and the use of virtual diagnostic clinics • Session structures, operating hours and any variations between sites
Date of Response: 08/06/2026
View Response: 11500.pdf
Freedom of Information Request Reference: 11499
Date Received: 18/05/2026
Summary:
I request the following information for the financial year 1 April 2026 – present, specifically relating to Long Covid, ME/CFS, and other Energy Limiting Conditions (ELCs). Where possible, please provide fully disaggregated figures, and clearly identify any gaps, exclusions, or data limitations. 1. Funding Allocation For all funding allocated to Long Covid, ME/CFS, and ELCs: • Provide total funding by source (core NHS Lothian budget, ring-fenced Scottish Government allocations, national or local grants, or other sources). • For each source, specify: o Allocated amount o Amount spent to date o Committed future spend (funds earmarked but not yet spent) o Underspends or unutilised funds • Include the date each funding allocation was approved and any conditions or restrictions attached to the funds. 2. Expenditure Provide a detailed breakdown of expenditure to date for 2026/2027, including: • Staffing: number of posts, full-time equivalents, role descriptions, total costs (salary + on-costs) • Service delivery: operational costs, contracts, third-party providers, clinical/non-clinical services • Evaluation, or monitoring costs specifically related to these conditions • Other operational costs, clearly specified If categories do not exist in the finance system, provide the closest equivalent and explain the categorisation. 3. Services & Pathways List all funded services, clinics, or care pathways for these conditions, including: • Scope and objectives • Eligibility criteria • Staffing and roles (FTE and job descriptions) • Delivery model: in-person, virtual, or hybrid • Physical or digital locations • Start date For multi-condition or cross-service pathways, clearly specify which patients with Long Covid, ME/CFS, or ELCs are included. 4. Patient Access • Provide total number of patients accessing each service since 1 April 2026. • Where possible, disaggregate by condition (Long Covid, ME/CFS, ELCs). • If exact disaggregation would breach confidentiality, provide anonymised aggregated figures, and specify the methodology used. • Include any patients referred but unable to access services and reasons. 5. Unallocated / Indirect Funding • Identify any funds allocated to Long Covid, ME/CFS, or ELCs that are not currently assigned to a specific service or pathway. • Include planned uses or timelines for these funds, if any. • Include any provisions held centrally for future allocation, and specify approval processes. 6. Remaining Budget • State the total unallocated budget for 2026/27 as of the date of this request. • Provide details of planned future allocations, including timelines and intended services. 7. Supporting Documentation Please provide all records used to compile the above information, including: • Spreadsheets, financial tables, or accounting systems • Board papers, committee reports, or meeting notes, emails • Service-level monitoring reports • Internal guidance documents, related emails and details of meetings or definitions used to classify funds or cover service provision or delivery.
Date of Response: 25/06/2026
View Response: 11499.pdf
Freedom of Information Request Reference: 11498
Date Received: 18/05/2026
Summary:
I am writing to you to request information under freedom of information legislation about suicides of people in mental health care. I am looking for the following information. 1a). How many people have completed suicide while in mental health wards? I am looking for these figures for 2023, 2024 and 2025. 1b). How many of these deaths have been subject to an investigation? Please categorise these by type ie SAER, suicide review or other type of investigation. 2a). How many people have completed suicide within 24 hours of being in contact with mental health services ? I am also looking for these figures for 2023, 2024 and 2025. 2b). How many of these deaths have been subject to an investigation? Please categorise these by type ie SAER, suicide review or other type of investigation.
Date of Response: 11/06/2026
View Response: 11498.pdf
Freedom of Information Request Reference: 11497
Date Received: 15/05/2026
Summary:
Please note for both questions, if a patient has received multiple injection/implants in the time period specified of January to April 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two. 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from January to April 2026: • Aflibercept - Eylea • Aflibercept - Biosimilar • Bevacizumab • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - including all Biosimilars 2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2026: • Aflibercept - Eylea • Aflibercept - Biosimilar • Bevacizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - including all Biosimilars
Date of Response: 12/06/2026
View Response: 11497.pdf
Freedom of Information Request Reference: 11496
Date Received: 15/05/2026
Summary:
Please provide the following information for the three most recent financial years for which complete data are held (2022/23, 2023/24 and 2024/25, or the latest equivalent three-year period): 1. The total number of patient and staff meals served across all premises and facilities managed by your health board (including acute hospitals, community hospitals, mental health facilities, and any other catering services). 2. The number and/or proportion of those meals that were supplied as halal (i.e. using halal-certified meat or prepared to halal dietary standards). Please break this down by facility type or site where possible (e.g. main acute hospital, community hospitals, other). 3. The total expenditure on food provision (patient meals, staff canteens, and any other catering) across your health board facilities. 4. The expenditure specifically on halal food or halal-certified meat/ingredients. If exact halal spend is not recorded separately, please provide the best available figure or estimate and explain the basis. 5. Any available data on the number of halal meal requests or uptake rates from patients, staff, or visitors. 6. Copies of any current policies, guidelines, procurement frameworks or contracts that relate to the provision of halal or other religious dietary requirements in patient and staff catering. 7. Any internal reports, assessments, equality impact assessments, or reviews produced since 1 April 2022 that discuss the provision, demand, or costs associated with halal food within the Health Board.
Date of Response: 12/06/2026
View Response: 11496.pdf
Freedom of Information Request Reference: 11495
Date Received: 15/05/2026
Summary:
Request in relation to personal information.
Date of Response: 04/06/2026
View Response: 11495.pdf
Freedom of Information Request Reference: 11494
Date Received: 14/05/2026
Summary:
Q1. How many patients were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 1.1 Glofitamab monotherapy 1.2 Glofitamab + Gemcitabine + Oxaliplatin Q2. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 2.1 Acalabrutinib (Calquence) 2.2 Ibrutinib (Imbruvica) 2.3 Pirtobrutinib (Jaypirca) 2.4 Venetoclax (Venclyxto) 2.5 Zanubrutinib (Brukinsa) 2.6 Rituximab 2.7 Obinutuzumab (Gazyvaro) Q3. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 3.1 Acalabrutinib (Calquence) 3.2 Ibrutinib (Imbruvica) 3.3 Pirtobrutinib (Jaypirca) 3.4 Venetoclax (Venclyxto) 3.5 Zanubrutinib (Brukinsa) 3.6 Obinutuzumab (Gazyvaro) 3.7 Rituximab Q4. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 4.1 Ibrutinib + Venetoclax 4.2 Obinutuzumab + Venetoclax 4.3 Ibrutinib monotherapy / maintenance 4.4 Venetoclax monotherapy 4.5 Venetoclax + Rituximab 4.6 Rituximab monotherapy 4.7 Rituximab + Fludarabine + Cyclophosphamide 4.8 Rituximab + R-CHOP 4.9 Rituximab + Bendamustine 4.10 Rituximab + Chlorambucil 4.11 Obinutuzumab + Chlorambucil 4.12 Acalabrutinib + Venetoclax 4.13 Acalabrutinib + Venetoclax + Obinutuzumab Q5. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available? 5.1 Acalabrutinib 5.2 Ibrutinib 5.3 Zanubrutinib 5.4 Ibrutinib + R-CHOP / R-DHAP 5.5 Pirtobrutinib
Date of Response: 12/06/2026
View Response: 11494.pdf
Freedom of Information Request Reference: 11493
Date Received: 13/05/2026
Summary:
I would like to know the number of under 18's who have self-presented and have been referred to hospitals/facilities by Health Care Professionals in the health board area for Mental Health concerns/incidents, including self-harm, overdoses, suicide attempts. I would also like to know how many under 18's have been admitted to Adolescent/Young People facilities in the health board area. Please provide the total figures for the following years: 2020, 2021, 2022, 2023, 2024, 2025 & 2026.
Date of Response: 11/06/2026
View Response: 11493.pdf
Freedom of Information Request Reference: 11492
Date Received: 13/05/2026
Summary:
The recent FT article that Palantir staff already have unlimited access to identifiable patient data, which could include our private medical history attached to our names causes me great concern. So far I have been unable to discover if our local NHS Trust has started or plans to use this software, so initially am asking you this 2-part question. Failing a yes/no answer, my next stage would be the FoI request which I would hope this request avoids.
Date of Response: 11/06/2026
View Response: 11492.pdf
Freedom of Information Request Reference: 11491
Date Received: 13/05/2026
Summary:
I am writing to request information regarding whether any of my personal data, medical records, patient information, or identifiable healthcare information held by NHS Lothian has ever been shared with, processed by, accessed by, or made available to Palantir Technologies, or any of its subsidiaries, affiliates, contractors, or associated entities. Specifically, I would like to know: • Whether any of my personal or medical information has been shared directly or indirectly with Palantir Technologies or related entities. • The legal basis relied upon for any such sharing or processing. • The categories of information involved. • The dates or periods during which any sharing or access took place. • The purpose of any data sharing or processing arrangement. • Whether my information was anonymised, pseudonymised, or fully identifiable. • Whether any third-party processors or subcontractors were involved.
Date of Response: 13/05/2026
View Response: 11491.pdf
Freedom of Information Request Reference: 11489
Date Received: 13/05/2026
Summary:
I am writing to you to request any information on all emergency department attendances for patients under 18-years of age (up to 17 years and 11 months) that were found to have SVT. For each case, I am looking for: Age, gender, treatment provided, whether treatment was successful and if not what happened after, and arrival method (highlighting those who were conveyed by ambulance).
Date of Response: 11/06/2026
View Response: 11489.pdf
Freedom of Information Request Reference: 11488
Date Received: 12/05/2026
Summary:
I would like to request the following information relating specifically to Medical (Doctor) staffing within your Trust. For the last three completed financial quarters, please provide: 1. The total spend on Medical Agency Doctors (locum doctors supplied via agencies). 2. The total spend on Medical Bank Doctors (locum doctors engaged via the Trust’s staff bank or internal arrangements). Where the information is readily available, please also provide a high level breakdown by grade or staff group, for example: - Consultant - Specialty Doctor / SAS - Registrar (ST3+) - SHO / Foundation / Trust Grade Optional contextual information (if held): 1. The average medical vacancy rate (%) for the same reporting period. 2. Confirmation of whether any agency medical shifts within this period were approved under “break glass” arrangements.
Date of Response: 11/06/2026
View Response: 11488.pdf
Freedom of Information Request Reference: 11484
Date Received: 11/05/2026
Summary:
Can you please provide an update on your Trust’s Infrastructure, including aspects of Hardware and Printing?
Date of Response: 05/06/2026
View Response: 11484.pdf
Freedom of Information Request Reference: 11482
Date Received: 11/05/2026
Summary:
I am writing to request a formal review of your response to my Freedom of Information request, reference 11330, dated 6 May 2026, concerning Palantir Technologies and patient data. I am grateful for the response provided. However, I have identified what appears to be a material internal contradiction between two of the answers given, and I request that this be reviewed and reconciled. I request that NHS Lothian review its response to Question 1 in light of its answer to Question 4, and provide: A clear explanation of how the DPIA in relation to Palantir Technologies software or services was scoped and conducted without any contact, meetings, correspondence, or discussions with Palantir Technologies Inc. or any of its subsidiaries or associated companies. Clarification of whether any contact, correspondence, or discussions took place with any third party acting on behalf of Palantir Technologies, or through any intermediary such as a procurement framework, shared services body, or another NHS organisation, that may not have been captured by the original answer to Question 1. A copy of the DPIA itself, or if NHS Lothian considers any part of it exempt from disclosure, a schedule of the exemptions claimed with reasons, and disclosure of any parts that are not exempt.
Date of Response: 16/06/2026
View Response: 11482.pdf
Freedom of Information Request Reference: 11481
Date Received: 08/05/2026
Summary:
Q1. How many patients were treated by the rheumatology department in the past 3 months with the following: •Tocilizumab – for any disease •Tocilizumab for rheumatoid arthritis (RA) only •Tocilizumab for giant cell arteritis (GCA) only Q2. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab? Q3. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab? Q4. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were: •Admitted as an inpatient •Treated in A&E
Date of Response: 08/06/2026
View Response: 11481.pdf
Freedom of Information Request Reference: 11480
Date Received: 08/05/2026
Summary:
1.Please describe your service and what you offer (e.g. autism diagnostic service; neurodevelopmental support service). 2.Please describe your triage process (e.g. separate referrals management team, paper screening of referrals by core team, initial screening assessments offered to clients). 3.How many people are currently awaiting diagnostic assessment (as of April 2026)? 4.What is the maximum waiting time for diagnostic assessment? 5.What percentage of referral were declined between April 2023-April 2026 and for what reason (common themes)? 6.How many complaints were received between April 2023-April 2026 (please describe common themes)? 7.What framework do you use for diagnostic assessment? (e.g. following NICE and/or AQAS guidelines). 8.Do you offer pre and/or post diagnostic interventions (if so which)? 9.If ADHD medication treatments (initiation and titration) are offered, what local arrangements do you have in place for shared care? 10.What is your staffing model? (mdt members, admin)
Date of Response: 08/06/2026
View Response: 11480.pdf
Freedom of Information Request Reference: 11479
Date Received: 08/05/2026
Summary:
FOI survey of ophthalmic support staff education and training.
Date of Response: 08/06/2026
View Response: 11479.pdf
Freedom of Information Request Reference: 11478
Date Received: 07/05/2026
Summary:
Adult ADHD Assessments 1. How many adults do you have waiting for an ADHD diagnosis at the moment? 2. How many adults were given an ADHD Assessment in the last year (1st April 2025 - 31st March 2026). 3. If an adult was referred to you now when would you expect them to be seen? 4. Please describe your current Adult ADHD Assessment pathway. Child ADHD Assessments 5. How many children do you have waiting for an ADHD diagnosis at the moment? 6. How many children were given an ADHD Assessment in the last year (1st April 2025 - 31st March 2026). 7. If a child was referred to you now when would you expect them to be seen? 8. Please describe your current Child ADHD Assessment pathway.
Date of Response: 08/06/2026
View Response: 11478.pdf
Freedom of Information Request Reference: 11477
Date Received: 06/05/2026
Summary:
Please include the following information for the following years 2022/23, 2023/24, 2024/25 and 2025/26 • The total value of compensation claims paid in respect of maternity claims, please include a break down by: o Claimant costs o The Trust’s legal costs • Total number of maternity compensation claims made, broken down by: o Settled with admission of liability o Settled without admission of liability o Failed claims • Total number of maternity claims currently open or in progress • A breakdown of the reasons for maternity compensation claims and the number of cases that fell into each category. o (for example Cerebral palsy and other brain injuries to the baby, stillbirth, neonatal death, other significant injury to the baby, maternal death, significant maternal injury, psychological injury etc) • For each year please provide the largest maternity compensation claim including information on: o Total damages paid o The category of the maternal injury
Date of Response: 01/06/2026
View Response: 11477.pdf
Freedom of Information Request Reference: 11476
Date Received: 07/05/2026
Summary:
This request covers two product groups commonly used together in ENT, head & neck, thyroid/parathyroid, and similar operations to monitor nerve activity during surgery. Theatres or Biomedical Engineering usually procures them. Specifically: • Capital equipment — small wheeled or table-top monitor consoles used in theatre (often called "nerve monitors", "IONM systems", or "nerve integrity monitors"). Listed in Section 1 below. • Disposables — single-use specialist endotracheal (breathing) tubes with built-in electrodes that detect nerve signals, and related single-use nerve-detecting electrodes/tubes. Listed in Section 2 below. To make the request as quick as possible, I have set out the form with the main UK manufacturers and products pre-populated. The Trust simply needs to fill in the numbers in the empty cells, and add anything not listed in the "Other" rows. Most of this should be answerable directly from the procurement system in well under an hour. Time period: capital equipment as currently in use (with year of acquisition); disposables for calendar years 2024, 2025, and 2026 to date. 1. Surgical nerve-monitoring systems (capital) — installed base These are the monitor consoles used in theatre. Please enter the number of consoles / systems currently in use for each model and the year(s) they were acquired (a year, or a range — e.g. "2019" or "2018 & 2022"). If a system in use is not listed, please add it in one of the rows at the bottom (manufacturer + model name). Medtronic NIM Vital Medtronic NIM 3.0 Inomed C2 NerveMonitor Inomed C2 Xplore Neurosign V4 Dr. Langer Medical Avalanche / nerve monitor Any other nerve-monitoring system / console not listed above Please specify manufacturer and model Any other nerve-monitoring system / console not listed above Please specify manufacturer and model 2. EMG endotracheal tubes & nerve-monitoring disposables — units purchased These are the single-use specialist tubes and electrodes purchased to use with the systems above. Please enter the number of units purchased in each calendar year (2024, 2025, and 2026 to date) for each product. If a product purchased is not listed, please add it in one of the rows at the bottom (manufacturer + product name). Medtronic TriVantage EMG Tube Medtronic Flex EMG Tube Inomed ALM Tube Inomed Laryngeal Electrode Select Dr. Langer Medical Adhesive tube electrode Dr. Langer Medical Electrode tube Any other EMG / nerve-monitoring endotracheal tube or electrode not listed above Please specify manufacturer and product name Any other EMG / nerve-monitoring endotracheal tube or electrode not listed above Please specify manufacturer and product name
Date of Response: 08/06/2026
View Response: 11476.pdf
Freedom of Information Request Reference: 11475
Date Received: 07/05/2026
Summary:
How many preventable deaths were there in children aged under 16 years old in 2019/20, 2020/21, 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26. Please break this down year-on-year, by condition/cause of death and by sex.
Date of Response: 11/06/2026
View Response: 11475.pdf
Freedom of Information Request Reference: 11474
Date Received: 07/05/2026
Summary:
Q1a - How many patients were treated with the following drugs from the following departments (for any disease) from the start of January 2026 to the end of March 2026? If Rheumatology cannot provide historic data, a snapshot of those currently being treated would be helpful. Please use the latest available 3 months if January to March is not available and specify which 3 months has been used. Adalimumab Bimekizumab Brodalumab Certolizumab Pegol Deucravacitinib Etanercept Etrasimod Filgotinib Golimumab Guselkumab Infliximab (Biosimilars) Infliximab (Remicade) Ixekizumab Mirikizumab Ozanimod Risankizumab Secukinumab Tildrakizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab
Date of Response: 09/06/2026
View Response: 11474.pdf
Freedom of Information Request Reference: 11473
Date Received: 07/05/2026
Summary:
How many patients under 16 years old died from complications relating to undiagnosed cancer in 2019/20, 2020/21, 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26. Please break this down year-on-year, by age groups and by sex.
Date of Response: 08/06/2026
View Response: 11473.pdf
Freedom of Information Request Reference: 11472
Date Received: 07/05/2026
Summary:
June 2020 1. In June 2020, the average time between the date on which a GP referred a patient to specialist NHS mental health services (including multi-professional Community Mental Health Teams and urgent referral services such as the Mental Health Assessment Service) on a routine/non urgent basis and the date on which the assessment took place. 2. In circumstances where a referral was made on the above basis, the average time between referral and the date on which the patient was assessed at home by the Intensive Home Treatment team or a consultant psychiatrist and/or CPN. 3. In June 2020, the average time between the date on which a GP referred a patient to specialist NHS mental health services on an urgent basis and the date on which the appointment took place. 4. In circumstances where a referral was made on the above basis, the average time between referral and the date on which the patient was assessed at home by the Intensive Home Treatment team or a consultant psychiatrist and/or CPN. 5. In June 2020, the average time between the date on which a GP referred a patient to specialist NHS mental health services on an emergency basis and the date on which the appointment took place. 6. In circumstances where a referral was made on the above basis, the average time between referral and the date on which the patient was assessed at home by the Intensive Home Treatment team or a consultant psychiatrist and/or CPN. July 2020 7. In July 2020, the average time between the date on which a GP referred a patient to specialist NHS mental health services on a routine/non urgent basis and the date on which the appointment took place. 8. In circumstances where a referral was made on the above basis, the average time between referral and the date on which the patient was assessed at home by the Intensive Home Treatment team or a consultant psychiatrist and/or CPN. 9. In July 2020, the average time between the date on which a GP referred a patient to specialist NHS mental health services on an urgent basis and the date on which the appointment took place. 10. In circumstances where a referral was made on the above basis, the average time between referral and the date on which the patient was assessed at home by the Intensive Home Treatment team or a consultant psychiatrist and/or CPN. 11. In July 2020, the average time between the date on which a GP referred a patient to a patient to specialist NHS mental health services on an emergency basis and the date on which the appointment took place. 12. In circumstances where a referral was made on the above basis, the average time between referral and the date on which the patient was assessed at home by the Intensive Home Treatment team or a consultant psychiatrist and/or CPN.
Date of Response: 08/06/2026
View Response: 11472.pdf
Freedom of Information Request Reference: 11471
Date Received: 07/05/2026
Summary:
• Spend on Insourcing from February 2026-end of April 2026, broken down by each specialty and subspecialty, and the insourcing company that was used, e.g. cardiology £1000- echo cardiogram £1000- company x £1000 • The budget for each specialty for insourcing • Confirm the contract start and end date for each specialty • What frameworks were used for each specialty and was there direct awards and if so, who was they awarded to and what specialty • What was the service, e.g. theatres, outpatient, or diagnostic
Date of Response: 11/06/2026
View Response: 11471.pdf
Freedom of Information Request Reference: 11468
Date Received: 06/05/2026
Summary:
I am writing to request information under the Freedom of Information (Scotland) Act 2002 regarding incidents, reviews and complaints involving delayed, missed or incorrect diagnosis. Please provide the following information for the period 1 January 2020 to the most recent available date. PART 1: Incident Reporting Data (Datix or equivalent) Using your incident reporting system (e.g. Datix), please provide: 1. Total incidents The number of incidents recorded under categories including: “delayed diagnosis” “missed diagnosis” “diagnostic error” (or equivalent categories used locally) 2. Harm severity breakdown A breakdown of these incidents by recorded harm level: No harm Low harm Moderate harm Severe harm Death 3. Time series The above data broken down by calendar year. 4. Service/specialty Where held, a breakdown by clinical area or specialty (e.g. emergency department, oncology, primary care interface). PART 2: Significant Adverse Events (SAEs) Please provide: 5. SAE volume The number of Significant Adverse Event (or equivalent) reviews where: delayed, missed or incorrect diagnosis was identified as a contributing factor 6. Outcome breakdown Of these, how many involved: Severe harm Patient death
Date of Response: 26/06/2026
View Response: 11468.pdf
Freedom of Information Request Reference: 11463
Date Received: 05/05/2026
Summary:
I would be grateful if you could provide the following information for the financial year 2025 / 2026 for your adult gender clinic service. Referrals, Discharges & Waiting List How many referrals received? How many people were discharged from the service? Number of people on the waiting list at the end of the financial year? Appointments How many appointments offered in total? How many appointments were not attended? Most common reason for non-attendance? How many 1st appointments offered? How many 2nd appointments offered? Average number of appointments offered per patient? Average number of appointments attended per patient? Average wait time between 1st and 2nd appointment in days? Average time between 1st appointment and discharge, where discharge is noted as treatment completed, in days? Staff How many clinical / diagnostic staff (FTE) employed at the GIC each year? How many administrative / support staff employed at the GIC each year? Breakdown of job roles / titles held by clinical & diagnostic staff at the GIC, including FTE / WTE for each role? Salary Band / Pay Rate for each job role? FTE / WTE of clinical / diagnostic staff trained or capable of delivering diagnostic initial assessments & follow up assessment appointments for Gender Dysphoria / Gender Incongruence? Indication of which job roles / tiles provide diagnostic initial assessments & follow up assessment appointments for Gender Dysphoria / Gender Incongruence? Budget Budget / Spend (total in £) for each year for the GIC? Breakdown of Budget / Spend for the year by : - Clinical / diagnostic staff - Administrative / Support staff - Administrative Costs - Other Costs In addition, please provide the following information. These can be treated as separate requests. Service User Transfers data For the financial year 2025/2026 How many people were transferred from other adult clinics? How many people were transferred from the GIDS service to the adult service? Whether these transfers were counted as referrals in referrals data above? Whether these transfers were included in the waiting list data above? Waiting Time Calculations & Guidance? Please provide copies of any algorithms, spreadsheets, formulae used by the clinic to calculate waiting time information published by your clinic Please provide copies of any guidance or processes issued to staff on the production of waiting time information published by your clinic Age Banding Please provide the following information for the same financial year: - A breakdown of referrals received by service user age (under 18, 18-25, 26 - 35, 36 - 45, 46 - 55, 56 - 65, 65+) - A breakdown of time waited for the current waiting list using the same age band criteria as above
Date of Response: 29/06/2026
View Response: 11463.pdf
Freedom of Information Request Reference: 11427
Date Received: 27/04/2026
Summary:
I would like to request copies of any current clinical guidelines, protocols, or care pathways used by your organisation relating to the assessment and management of the latent phase of labour (early labour) within maternity services. If this is contained within general intrapartum care clinical guidelines then please send a copy of these.
Date of Response: 29/06/2026
View Response: 11427.pdf
Freedom of Information Request Reference: 11426
Date Received: 27/04/2026
Summary:
Average waiting time for gender reassignment surgery (between being listed for surgery and having first surgery) for the last five years of available data. Could this please be broken down into types of surgery Number of individuals awaiting gender reassignment surgery after being listed for surgery for the last five years of available data. Total waiting time for gender reassignment surgery from GP referral to having first surgery for last five years of available data. The number of gender reassignment procedures done on average per week referred from your region, according to centre for the last year of available data (just one figure is fine). The number of individuals wishing to retransition following their surgery per year for the last 5 years of available data.
Date of Response: 29/06/2026
View Response: 11426.pdf
Freedom of Information Request Reference: 11406
Date Received: 20/04/2026
Summary:
I request that NHS Lothian: Conduct a full review of FOI 11301. Confirm whether the requested documents exist. Provide the documents, or apply the correct exemptions with justification. Provide working public links where Section 25 is applied, including justification of how each link answers the question asked. Provide any internal policies, procedures, guidance, or training materials relating to communication‑related reasonable adjustments.
Date of Response: 22/06/2026
View Response: 11406.pdf
Freedom of Information Request Reference: 11404
Date Received: 20/04/2026
Summary:
I am requesting the following information in relation to diagnostic ultrasound equipment at [Trust/Clinic Name] for the last 12 months: 1. A list of all diagnostic ultrasound scanning systems, including: o Manufacturer o Model o Date of manufacture 2. For each ultrasound system listed: o The date of the most recent annual Quality Assurance (QA) check o Whether the annual QA was carried out internally (e.g. by Medical Physics / Clinical Engineering) or by an external provider o The date of the most recent service for each ultrasound system by which provider.
Date of Response: 26/06/2026
View Response: 11404.pdf
Freedom of Information Request Reference: 11402
Date Received: 20/04/2026
Summary:
I refer to the guidance issued by Dr Sharon Smith, Consultant Psychiatrist and Clinical Director, REAS Community Psychiatry, dated September 2024, where she discusses "Queries from patients regarding 'shared care'". In it, Dr Smith stated as follows: "The private clinics ask the GPs if they are willing to enter into a shared care agreement with themselves for specific patients and this is at the GP's discretion but the majority decline to do so until me patient is in local NHS secondary care services." In accordance with the Freedom of Information (Scotland) Act 2002, please provide me with all information held by NHS Lothian which was relied upon to make this assessment that the "majority decline".
Date of Response: 26/06/2026
View Response: 11402.pdf
Freedom of Information Request Reference: 11373
Date Received: 07/04/2026
Summary:
1) Would you please be able to tell me how many patient falls were recorded in the previous 12 months at across WGH, REH, RIE. If possible, I would like to know how these falls are classified and whether/how many patients fell from their bedside chair 2) I would also like to request a breakdown of the Trust’s hospital acquired pressure injuries by grade, and if possible, a report of how many pressure injuries were present on admission by which grade, also over the preceding 12 months, also for West General Hospital
Date of Response: 01/06/2026
View Response: 11373.pdf
Freedom of Information Request Reference: 11364
Date Received: 07/04/2026
Summary:
relating to Midwifery Safe Staffing and workforce planning for the financial year years 2024/2025 and 2025/ 2026 (up to 31st March 2026) Specifically, all documentary evidence of application of all aspects of the common staffing methodology as per DL (2024) 05 Health and Care (Staffing) (Scotland) Act 2019 – The Common Staffing Method and Staffing Level Tool Which states that: ‘The application of the CSM will support NHS Boards to ensure appropriate staffing, the health, wellbeing and safety of patients and the provision of safe and high-quality care’ In addition, that account has been taken in workforce planning that the current maternity tool does not cover the full extent of modern maternity services and that ‘The use of the Professional Judgement Tool, alongside other elements of the CSM, will enable a more accurate picture of staffing requirements and help mitigate against some of the risks and limitations of the existing Staffing Level Tool. For each financial year: 1. Did you run the maternity tool (in line with H&CSA 2019) 2. Did you document all parts of the common staffing methodology? 3. Please share the CSM outcomes that were shared at board level for consideration for midwifery staffing and any associated workforce plan 4. Please share any amendments that were requested to midwifery funded establishment arising from the output from the tool, professional judgement and all other aspects of CSM. (existing establishment and requested) 5. Any amendments that were made to midwifery funded establishment arising from question 4. 6. Please share broken down by registered & unregistered, care setting and skill mix and specialist and leadership roles. 7. Community, acute or integrated broken down by care setting 8. Specific specialist and education roles asked for and WTE approved 9. Specific leadership roles asked for and WTE approved 10. Number of Newly qualified midwives asked for and WTE (and number) approved 11. Pre and post CSM establishments broken down by filled unfilled 12. Share Documents that describes what was asked for and what was approved for recruitment. 13. Share roles not asked for but that you believe is required. B: I am also writing to request information under the Freedom of Information (Scotland) Act 2002 in relation to: 1. predicted absence allowance as defined in Name of measure: predictable absence allowance in maternity in 2024/2025 and 2025/2026. 2. Protected learning time as per NHS Circular: PCS(AFC)2024/1 Protecting learning time for Agenda for Change staff in NHS Scotland statutory and mandatory training as well as the 35 hours every three years for revalidation in addition to further training and development through PDP. 14. Share maternity /paternity leave in each financial year (by grade and setting ) 15. Share sick leave in each financial year (by grade and setting) 16. Study leaves in each financial year (by grade) 17. All other leave by grade and setting 18. Total percentage of each absence and total relative to establishment
Date of Response: 22/06/2026
View Response: 11364.pdf
Freedom of Information Request Reference: 11470
Date Received: 06/05/2026
Summary:
During the period of January 2024-March 2026, how many candidates applied for jobs under the Guaranteed Interview scheme? If possible, could I get a breakdown of how many candidates applied for each 'job family' (admin role, clinical roles, etc).
Date of Response: 11/06/2026
View Response: 11470.pdf
Freedom of Information Request Reference: 11469
Date Received: 06/05/2026
Summary:
Question One: How many patients has your trust treated in the past six months (for any disease) with the following drugs: Aubagio (teriflunomide) Avonex (interferon beta-1a) Betaferon (interferon beta-1b) Brabio (glatiramer acetate) Copaxone (glatiramer acetate) Extavia (beta interferon-1b) Gilenya (fingolimod) Kesimpta (ofatumumab) Lemtrada (alemtuzumab) Mavenclad (cladribine) Mayzent (siponimod) Ocrevus (ocrelizumab) Plegridy (peginterferon beta-1a) Ponvory (ponesimod) Rebif (beta interferon-1a) Tecfidera (dimethyl fumarate) Tysabri (natalizumab) Tysabri (natalizumab) Pre-filled syringes only Vumerity (diroximel fumarate) Zeposia (ozanimod) Fingolimod generic Tyruko (Natalizumab Biosimilar) Briumvi (ublituximab) Dimethyl fumarate generic Teriflunomide generic Question Two: How many patients has your trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months? Question Three: How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?
Date of Response: 01/06/2026
View Response: 11469.pdf
Freedom of Information Request Reference: 11467
Date Received: 06/05/2026
Summary:
I am requesting the following: • To the FOI Office: Under FOISA 2002, please provide the written policy or Standard Operating Procedure (SOP) that outlines this 10-day deactivation/removal window for patient clinical correspondence on the NHS Lothian portal.
Date of Response: 08/06/2026
View Response: 11467.pdf
Freedom of Information Request Reference: 11466
Date Received: 06/05/2026
Summary:
1. Does the Trust currently use, or have formal plans to trial or implement, a Non-Visual Patient Safety Aid (NVPSA) - for example, Safehinge Primera’s "Project X", “Smart Ward” or other radar-based motion tracking - within ward bedrooms, Section 136 suites, and/or seclusion rooms? 2. If the response to the above question is ‘yes’, please provide the following information: 2.1. The number of wards, 136 suites, and seclusion rooms where the technology is deployed (please provide ward names and type of ward). 2.2. The current Policy or Standard Operating Procedure (SOP) governing the use of this technology, including details of your consent process. 2.3. The Data Protection Impact Assessment (DPIA). 2.4. The Equality Impact Assessment (EqIA). 2.5. The Clinical Safety Case Report and Clinical Hazard Log (as required by DCB0129/DCB0160 standards). Please also provide a copy of any entries on the Trust’s Organisational Risk Register that relate to "transferred risks" or residual risks identified during the deployment of this technology. 2.6. The contract start and end dates for the current provision. 2.7. Minutes of meetings where the decision to adopt, trial, continue, expand, or cease the use of the technology was made, including the rationale for the decision. 2.8. Copies of patient-facing information, such as posters, leaflets, or privacy notices provided to service users and carers. 2.9. Copies of all staff training materials or presentation slides relating to the use of NVPSA, including details of the Trust’s competency assurance framework, the mandated frequency of refresher training and the compliance rate (percentage of staff on the relevant wards who have completed training).
Date of Response: 02/06/2026
View Response: 11466.pdf
Freedom of Information Request Reference: 11465
Date Received: 06/05/2026
Summary:
I am looking for the reviewed version, status update, or progress report relating to the Royal Infirmary of Edinburgh Maternity Inspection action plan, October 2025. The published action plan states a review date of 29 January 2026. Please could you confirm whether a reviewed or updated version of the action plan exists and, if so, provide a copy.
Date of Response: 11/06/2026
View Response: 11465.pdf
Freedom of Information Request Reference: 11464
Date Received: 05/05/2026
Summary:
Please could you provide the following details regarding the use of slide sheets within your organisation: 1. The types/brands of slide sheets currently in use across your Trust (e.g. disposable, reusable, tubular, bariatric, etc.), including product names where available. 2. The names of the suppliers/manufacturers you currently procure slide sheets from. 3. The total quantity of slide sheets purchased in the last 12 months, broken down by product type if possible. 4. The total spend on slide sheets in the last 12 months. 5. Details of any current contracts or frameworks used for the procurement of slide sheets, including: - Framework provider (e.g. NHS Supply Chain or other) - Contract start and end dates 6. Whether your Trust has made any recent changes (in the last 24 months) to slide sheet suppliers or products, and if so, which suppliers/products were replaced and which were introduced. 7. The department responsible for procurement of moving & handling consumables (e.g. procurement team, tissue viability, moving & handling advisors).
Date of Response: 01/06/2026
View Response: 11464.pdf
Freedom of Information Request Reference: 11462
Date Received: 06/05/2026
Summary:
Please provide the following information for NHS Lothian: 1. Catering provision - For each hospital site, whether catering is: - provided in-house, or - outsourced (and to which provider) 2. Outsourced contracts - Name of provider(s) - Contract start and end dates - Scope (e.g. patient meals, staff/retail catering) 3. Governance - Names of committees or groups responsible for overseeing catering services Date range: Current information as of the date of this request onwards (5/5/26-)
Date of Response: 11/06/2026
View Response: 11462.pdf
Freedom of Information Request Reference: 11461
Date Received: 29/04/2026
Summary:
The average cost per occupied bed day for each of the following inpatient psychiatric ward types at the Royal Edinburgh Hospital: Acute adult psychiatric wards Intensive Psychiatric Care Unit (IPCU) Rehabilitation wards If ward-specific figures are not available, the average cost per occupied bed day for adult inpatient psychiatric care across NHS Lothian as a whole. The average length of stay for a compulsory detention under the Mental Health (Care and Treatment) (Scotland) Act 2003 within NHS Lothian, for the most recent year available. The total annual cost to NHS Lothian of inpatient psychiatric care, broken down by ward type if possible, for the most recent financial year available.
Date of Response: 28/05/2026
View Response: 11461.pdf
Freedom of Information Request Reference: 11460
Date Received: 29/04/2026
Summary:
I am conducting research into regional variation in access to breast reconstruction services across Scotland and would be grateful for the following information for the most recent available year (or the last 3 years if easier to provide): 1. Does your Health Board provide breast reconstruction surgery directly for patients undergoing mastectomy for breast cancer? 2. If breast reconstruction is not provided within your Health Board, which Health Board(s) or external centre(s) are patients referred to? 3. Which types of breast reconstruction are available to patients within your Board or via formal referral pathways? Which types of breast reconstruction are available to patients within your Board or via formal referral pathways? * Implant-based reconstruction * Latissimus dorsi flap * DIEP flap * Other autologous flap reconstruction 4. Are there any formal eligibility criteria, thresholds, or policies for access to breast reconstruction (including immediate or delayed reconstruction), such as: * Limits on number/type of revision procedures * Limits on time period in which the revision procedures needs to be undertaken * BMI thresholds * Smoking cessation requirements * Diabetes control requirements * Comorbidity-related exclusions * Other access criteria Please provide copies of any relevant written policies where available. 5. Is there availability/funding for breast surgery on the contralateral breast (the breast without breast cancer) for means of providing symmetry to any planned reconstructive procedure of the breast with breast cancer? 6. What is the average waiting time for: * Immediate breast reconstruction following mastectomy * Delayed breast reconstruction following mastectomy? 7. Approximately how many patients per year are referred outside your Health Board for breast reconstruction services? Approximately how many patients per year are referred outside your Health Board for breast reconstruction services?
Date of Response: 08/06/2026
View Response: 11460.pdf
Freedom of Information Request Reference: 11459
Date Received: 05/05/2026
Summary:
My query is in relation to patients who receive treatment at private hospitals, but are admitted by emergency during or after treatment to NHS hospitals in your health board area. To ask, how many patients have been admitted by emergency to hospitals in your area either directly from private hospitals, or immediately after receiving treatment in private hospitals. Could this be broken down by the following years. 2021 2022 2023 2024 2025 In addition, if it was possible to disclose the type or nature of the admission, that would be appreciated.
Date of Response: 12/06/2026
View Response: 11459.pdf
Freedom of Information Request Reference: 11458
Date Received: 05/05/2026
Summary:
To ask for a list of items that have been reported as stolen from hospitals, health centres and any other NHS building in your area. Could this list please be provided for the following years. 2023 2024 2025
Date of Response: 08/06/2026
View Response: 11458.pdf
Freedom of Information Request Reference: 11457
Date Received: 05/05/2026
Summary:
To ask how much money your health board has paid to foreign countries for healthcare provided to UK citizens in the following years. 2023 2024 2025 In addition, could this be broken down by the countries which received the payment and, if possible, the nature of the treatment provided.
Date of Response: 01/06/2026
View Response: 11457.pdf
Freedom of Information Request Reference: 11456
Date Received: 05/05/2026
Summary:
Question 1. • The latest version of the local guidelines used for the treatment of Uterine Fibroids. • If there are no local guidelines written, then which National Guidelines are your clinicians directed to use? Question 2. • The latest version of the local guidelines used for the treatment of Endometriosis. • If there are no local guidelines written, then which National Guidelines are your clinicians directed to use? Question 3. • Which Hospitals within your catchment area are centres for the treatment of Uterine Fibroids and Endometriosis? Question 4. • Can I have a link to the formulary of formularies that cover the hospitals listed in Question 3.
Date of Response: 08/06/2026
View Response: 11456.pdf
Freedom of Information Request Reference: 11455
Date Received: 05/05/2026
Summary:
Could you please let me know which active primary care rebate schemes your organisation are currently signed up to? Could you please provide the start and end dates of the contracts.
Date of Response: 08/06/2026
View Response: 11455.pdf
Freedom of Information Request Reference: 11454
Date Received: 05/05/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period available? 1.1 Abemaciclib (Verzenios) 1.2 Alpelisib (Piqray) 1.3 Elacestrant (Orserdu) 1.4 Fulvestrant (fulvestrant or Faslodex) 1.5 Inavolisib (Inaqovi) 1.6 Palbociclib (Ibrance) 1.7 Ribociclib (Kisqali) 1.8 Capivasertib (Truqap) 1.9 Talazoparib (Talzenna) 1.10 Olaparib (Lynparza) Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available? 2.1 Abemaciclib (Verzenios) 2.2 Ribociclib (Kisqali) 2.3 Olaparib (Lynparza) Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available? 3.1 Abemaciclib (Verzenios) 3.2 Ribociclib (Kisqali) Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period available? 4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) 4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) 4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) 4.4 Inavolisib (Inaqovi) + Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of January 2026 and the end of March 2026? 5.1 Olaparib - All types of breast cancer 5.2 Olaparib - Locally advanced or metastatic breast cancer 5.3 Talazoparib – All types of breast cancer Q6. How many Endometrial Cancer (C54.1) patients by subtype deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) are treated with the following within the last 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available? 6.1 Dostarlimab + Carboplatin + Paclitaxel 6.2 Pembrolizumab + Carboplatin + Paclitaxel 6.3 Pembrolizumab + Lenvatinib 6.4 Dostarlimab as monotherapy at cycle 1 6.5 Dostarlimab as monotherapy maintenance (cycle 7+) 6.6 Pembrolizumab as monotherapy at cycle 1 6.7 Pembrolizumab as monotherapy maintenance (cycle 7+) 6.8 Durvalumab + Carboplatin + Paclitaxel 6.9 Durvalumab + Carboplatin + Paclitaxel + Olaparib (Poly ADP-ribose Polymerase Inhibitor)
Date of Response: 02/06/2026
View Response: 11454.pdf
Freedom of Information Request Reference: 11453
Date Received: 05/05/2026
Summary:
In the period 1st February 2026 to 30th April 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name In the period 1st February 2026 to 30th April 2026 please provide a breakdown of: • Total trust spend with off-framework agencies for locums doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name In the period 1st February 2026 to 30th April 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum doctors for the period 1st February 2026 to 30th April 2026 Please confirm the name of the framework used for the supply of locum doctors in your trust.
Date of Response: 08/06/2026
View Response: 11453.pdf
Freedom of Information Request Reference: 11452
Date Received: 05/05/2026
Summary:
I would like to enquire if NHS Lothian uses a specific Venous thromboembolism (VTE) prophylaxis guideline/risk assessment tool for patients on critical/intensive care units.
Date of Response: 03/06/2026
View Response: 11452.pdf
Freedom of Information Request Reference: 11450
Date Received: 27/04/2026
Summary:
Please can you tell me the attendance numbers to the date for the GP walk-in clinic in Wester Hailes. A weekly count since it opened would be my ideal if possible and can I please have it in MS Excel.
Date of Response: 12/06/2026
View Response: 11450.pdf
Freedom of Information Request Reference: 11449
Date Received: 01/05/2026
Summary:
How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: · Adalimumab - Humira · Adalimumab Biosimilar · Apremilast - Otezla · Apremilast generic · Bimekizumab · Brodalumab · Certolizumab · Deucravacitinib · Dimethyl fumarate · Etanercept - Enbrel · Etanercept Biosimilar · Guselkumab · Infliximab - Remicade · Infliximab Biosimilar · Ixekizumab · Risankizumab · Secukinumab · Tildrakizumab · Ustekinumab - Stelara · Ustekinumab Biosimilar · Omalizumab · Spesolimab
Date of Response: 01/06/2026
View Response: 11449.pdf
Freedom of Information Request Reference: 11448
Date Received: 30/04/2026
Summary:
With regard to NHS Education for Scotland's 'Softer Landing, Safer Care' initiative: How many international medical graduates in NHS Lothian undertook a two-week shadowing placement prior to the start of their general practice posting, in each of the last five years. With regards to support international medical graduates more generally: Are there any other initiatives by NHS Lothian to support international medical graduates prior to the start of their general practice posting?
Date of Response: 29/05/2026
View Response: 11448.pdf
Freedom of Information Request Reference: 11447
Date Received: 30/04/2026
Summary:
I’m writing to request information under the Freedom of Information Act 2000 regarding staffing within your Trust’s fertility services, specifically any IVF or assisted conception units. I’d be grateful if you could provide the following: 1. Workforce composition The number of staff working in fertility nursing/practitioner roles within your IVF or assisted conception service A breakdown of these staff by professional registration: Registered Nurse (RN) Registered Midwife (RM) Dual RN/RM (if applicable) 2. Role requirements For fertility nursing/practitioner roles within IVF/assisted conception services, does your Trust require applicants to be: Registered Nurses only Registered Midwives only Either RN or RM A copy of the most recent job description(s) and person specification(s) for these roles 3. Scope of practice Are there any duties within these roles that are undertaken by Registered Nurses but not by Registered Midwives? If yes, please outline which duties and the rationale for this distinction 4. Training and competency Do you provide additional training for staff entering fertility roles from either a nursing or midwifery background? If so, are there any differences in training pathways between the two groups? 5. Workforce approach Any information, policy, or guidance your Trust uses when deciding whether to employ Registered Nurses, Registered Midwives, or both within IVF/assisted conception services
Date of Response: 28/05/2026
View Response: 11447.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS
NHS Lothian Charity Logo
Tel: +44 (0)131 465 5850
Email: loth.charity@nhs.scot

Scottish Registered Charity No: SC007342
The official charity of NHS Lothian.
From the everyday to the transformational, we support NHS Lothian to excel for all the communities it serves: patients, families, carers and staff.
Making healthcare better, together.
Find out more about NHS Lothian Charity
Donate